PriceTargets.com logo

Gossamer Bio - GOSS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $256.00
  • Forecasted Upside: 2,235.77%
  • Number of Analysts: 9
  • Breakdown:
  • 2 Sell Ratings
  • 3 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$10.96 As of 09/16/2026 05:00 PM ET
▲ +0.58 (5.59%)

This chart shows the closing price for GOSS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Gossamer Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GOSS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GOSS

Analyst Price Target is $256.00
▲ +2,235.77% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Gossamer Bio in the last 3 months. The average price target is $256.00, with a high forecast of $720.00 and a low forecast of $80.00. The average price target represents a 2,235.77% upside from the last price of $10.96.

This chart shows the closing price for GOSS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 9 investment analysts is to hold stock in Gossamer Bio. This rating has held steady since February 2026, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
3/20/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 2 sell ratings
Ratings as of
6/18/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
8/17/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
9/16/2026

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/27/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
8/27/2026HC WainwrightReiterated RatingBuy ➝ Buy
8/14/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
7/28/2026Leerink PartnersUpgradeMarket Perform ➝ Outperform$80.00
7/27/2026HC WainwrightReiterated RatingBuy ➝ Buy
6/25/2026HC WainwrightLower TargetBuy ➝ Buy$400.00 ➝ $160.00
5/26/2026HC WainwrightReiterated RatingBuy ➝ Buy$400.00
5/19/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
4/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/23/2026Cantor FitzgeraldReiterated RatingOverweight ➝ Neutral
3/6/2026HC WainwrightLower TargetBuy ➝ Buy$800.00 ➝ $400.00
3/5/2026OppenheimerLower TargetOutperform ➝ Outperform$960.00 ➝ $240.00
2/24/2026BarclaysDowngradeOverweight ➝ Underweight
2/24/2026Royal Bank Of CanadaUpgradeOutperform
2/24/2026Leerink PartnersDowngradeStrong-Buy ➝ Hold
2/24/2026Leerink PartnersReiterated RatingOutperform ➝ Market Perform$480.00 ➝ $80.00
2/24/2026The Goldman Sachs GroupDowngradeStrong-Buy ➝ Hold
2/24/2026WedbushReiterated RatingOutperform ➝ Neutral$480.00 ➝ $80.00
1/27/2026BarclaysInitiated CoverageEqual Weight ➝ Overweight$720.00
1/27/2026BarclaysInitiated CoverageEqual Weight ➝ Overweight$720.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/22/2026HC WainwrightReiterated RatingBuy ➝ Buy$800.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/11/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
8/6/2025WedbushBoost TargetOutperform ➝ Outperform$320.00 ➝ $400.00
7/14/2025ScotiabankInitiated CoverageSector Outperform$880.00
5/16/2025The Goldman Sachs GroupBoost TargetBuy ➝ Buy$560.00 ➝ $640.00
5/16/2025WedbushReiterated RatingOutperform ➝ Outperform$320.00 ➝ $320.00
4/17/2025The Goldman Sachs GroupLower TargetBuy ➝ Buy$640.00 ➝ $560.00
3/18/2025HC WainwrightReiterated RatingBuy ➝ Buy$800.00 ➝ $800.00
3/14/2025WedbushReiterated RatingOutperform ➝ Outperform$320.00 ➝ $320.00
1/30/2025HC WainwrightReiterated RatingBuy ➝ Buy$800.00 ➝ $800.00
11/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$800.00 ➝ $800.00
9/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$800.00 ➝ $800.00
8/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$800.00 ➝ $800.00
8/13/2024WedbushReiterated RatingOutperform ➝ Outperform$320.00 ➝ $320.00
6/25/2024OppenheimerInitiated CoverageOutperform$720.00
6/17/2024The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$640.00 ➝ $640.00
5/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$800.00
5/8/2024WedbushReiterated RatingOutperform ➝ Outperform$320.00
5/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$800.00
4/5/2024WedbushInitiated CoverageOutperform$320.00
3/27/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$1,200.00
3/6/2024WedbushReiterated RatingOutperform ➝ Outperform$480.00
3/6/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$720.00 ➝ $640.00
3/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$800.00
1/8/2024HC WainwrightBoost TargetBuy ➝ Buy$400.00 ➝ $800.00
12/19/2023WedbushReiterated RatingOutperform ➝ Outperform$480.00
11/10/2023WedbushBoost TargetOutperform ➝ Outperform$400.00 ➝ $480.00
8/11/2023WedbushReiterated RatingOutperform ➝ Outperform$400.00
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$400.00
7/27/2023UBS GroupDowngradeBuy ➝ Neutral$640.00 ➝ $100.00
7/26/2023HC WainwrightReiterated RatingBuy ➝ Buy$400.00
7/21/2023WedbushReiterated RatingOutperform ➝ Outperform$560.00 ➝ $400.00
3/21/2023WedbushReiterated RatingOutperform$560.00
3/21/2023BarclaysLower TargetEqual Weight$160.00 ➝ $120.00
3/7/2023Raymond James FinancialDowngradeOutperform ➝ Market Perform$400.00
2/28/2023GuggenheimInitiated CoverageNeutral
12/12/2022EvercoreLower Target$560.00
12/8/2022HC WainwrightLower TargetBuy$2,000.00 ➝ $400.00
12/7/2022Bank of AmericaLower Target$1,200.00 ➝ $560.00
12/7/2022The Goldman Sachs GroupLower TargetBuy$1,760.00 ➝ $800.00
12/7/2022UBS GroupLower TargetBuy$1,520.00 ➝ $640.00
12/7/2022JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight
12/7/2022BarclaysDowngradeOverweight ➝ Equal Weight$1,440.00 ➝ $160.00
12/7/2022Sumitomo Mitsui Financial GroupDowngradeOutperform ➝ Neutral$240.00
12/7/2022Leerink PartnersLower TargetOutperform$1,200.00 ➝ $800.00
11/17/2022Raymond James FinancialLower TargetOutperform$1,440.00 ➝ $1,200.00
10/20/2022The Goldman Sachs GroupInitiated CoverageBuy$1,760.00
10/13/2022HC WainwrightBoost Target$1,600.00 ➝ $2,000.00
9/21/2022JPMorgan Chase & Co.Initiated CoverageNeutral$1,360.00
9/19/2022WedbushInitiated CoverageOutperform$1,920.00
8/17/2022BarclaysBoost TargetOverweight$960.00 ➝ $1,440.00
7/14/2022HC WainwrightReiterated RatingBuy$1,600.00
7/14/2022Raymond James FinancialBoost TargetOutperform$800.00 ➝ $1,120.00
5/9/2022Cantor FitzgeraldReiterated RatingOverweight
4/26/2022Raymond James FinancialLower TargetOutperform$1,520.00 ➝ $800.00
4/26/2022BarclaysLower TargetOverweight$1,440.00 ➝ $960.00
4/26/2022HC WainwrightLower Target$2,000.00 ➝ $1,600.00
4/25/2022Piper SandlerLower Target$2,080.00 ➝ $1,200.00
4/18/2022Raymond James FinancialInitiated CoverageOutperform$1,520.00
4/6/2022UBS GroupInitiated CoverageBuy$1,520.00
1/10/2022Sumitomo Mitsui Financial GroupUpgradeNeutral ➝ Outperform$1,920.00
1/10/2022CitigroupUpgradeNeutral ➝ Outperform$1,920.00
11/9/2021Leerink PartnersBoost TargetOutperform$1,200.00 ➝ $1,280.00
10/18/2021Cantor FitzgeraldReiterated RatingOverweight
10/14/2021Leerink PartnersInitiated CoverageBuy
9/20/2021Piper SandlerInitiated CoverageBuy$2,080.00
(Data available from 9/17/2021 forward)

News Sentiment Rating

0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2026
  • 1 very positive mentions
  • 24 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2026
  • 2 very positive mentions
  • 57 positive mentions
  • 5 negative mentions
  • 6 very negative mentions
Mentions as of
4/19/2026
  • 0 very positive mentions
  • 101 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
5/19/2026
  • 5 very positive mentions
  • 54 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2026
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2026
  • 0 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2026
  • 0 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/16/2026

Current Sentiment

  • 0 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Gossamer Bio logo
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $10.96
Low: $9.96
High: $11.24

50 Day Range

MA: $13.21
Low: $10.38
High: $16.54

52 Week Range

Now: $10.96
Low: $9.10
High: $309.60

Volume

271,138 shs

Average Volume

284,200 shs

Market Capitalization

$32.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2

Frequently Asked Questions

What sell-side analysts currently cover shares of Gossamer Bio?

The following sell-side analysts have issued research reports on Gossamer Bio in the last year: Barclays PLC, Cantor Fitzgerald, HC Wainwright, Leerink Partners, Oppenheimer Holdings, Inc., Royal Bank Of Canada, The Goldman Sachs Group, Inc., Wall Street Zen, Wedbush, and Weiss Ratings.
View the latest analyst ratings for GOSS.

What is the current price target for Gossamer Bio?

0 Wall Street analysts have set twelve-month price targets for Gossamer Bio in the last year. Their average twelve-month price target is $256.00, suggesting a possible upside of 2,235.8%. Barclays PLC has the highest price target set, predicting GOSS will reach $720.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $80.00 for Gossamer Bio in the next year.
View the latest price targets for GOSS.

What is the current consensus analyst rating for Gossamer Bio?

Gossamer Bio currently has 2 sell ratings, 3 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GOSS, but not buy more shares or sell existing shares.
View the latest ratings for GOSS.

What other companies compete with Gossamer Bio?

Other companies that are similar to Gossamer Bio include OnKure Therapeutics, Tiziana Life Sciences, Promis Neurosciences, enGene and Cibus. Learn More about companies similar to Gossamer Bio.

How do I contact Gossamer Bio's investor relations team?

Gossamer Bio's physical mailing address is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. The company's listed phone number is (858) 684-1300 and its investor relations email address is [email protected]. The official website for Gossamer Bio is www.gossamerbio.com. Learn More about contacing Gossamer Bio investor relations.